

Hereditary Angioedema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

<https://marketpublishers.com/r/HD5E4276B1A0EN.html>

Date: May 2024

Pages: 139

Price: US\$ 6,499.00 (Single User License)

ID: HD5E4276B1A0EN

Abstracts

The 7 major Hereditary Angioedema markets reached a value of US\$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 3.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.1% during 2024-2034.

Hereditary Angioedema Market is currently witnessing strong growth driven by advances in identifying mechanisms of angioedema and developing modern safe and effective drugs to treat the disease. Furthermore, increasing global accessibility of advanced diagnostic tools and medications and improving drug development times have also created a positive impact on the market. Hereditary angioedema, or HAE, refers to a rare genetic disorder that is caused by dysfunctional or lack of C1-inhibitor protein. This condition is inherited in an autosomal dominant pattern, implying one copy of the altered gene in each cell is enough to cause the indication. It is characterized by recurrent episodes of rapid, severe, subcutaneous, and submucosal swelling of the face, hands, airways, intestinal tract, trachea, larynx, or tongue without the appearance of urticarial lesions. Hereditary angioedema affects the blood vessels and leads to extreme pain, nausea, vomiting, fatigue, diarrhea, muscle ache, tingling, headache, abdominal pain, hoarseness, and mood swings. It also results in fluid leakage through the walls of blood vessels into body tissues. Hereditary angioedema (HAE) affects around 1 in 50,000 of the population and does not show ethnic variation in frequency. Similar to other rare conditions, there is often a delay to diagnosis the indication, resulting in patients not receiving appropriate treatment at the right time.

IMARC Group's new report "Hereditary Angioedema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034". provides an exhaustive analysis of the Hereditary Angioedema market in the United States, EU5

(Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Hereditary Angioedema market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Hereditary Angioedema across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Hereditary Angioedema and also represents the largest market for Hereditary Angioedema treatment. Furthermore, the current Hereditary Angioedema treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Hereditary Angioedema market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, Current and Future Epidemiology Scenario

Historical, Current and Future Performance of the Hereditary Angioedema Market

Historical, Current and Future Performance of Various Therapeutic Categories in the Hereditary Angioedema Market

Sales of Various Drugs Across the Hereditary Angioedema Market

Reimbursement Scenario in the Hereditary Angioedema Market

Competitive Landscape:

This report also provides a detailed analysis of the current Hereditary Angioedema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the Hereditary Angioedema market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?

What was the country-wise size of the Hereditary Angioedema market across the seven major markets in 2023 and how will it look like in 2034?

What is the growth rate of the Hereditary Angioedema market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the Hereditary Angioedema market?

Epidemiology Insights

What is the size of the Hereditary Angioedema patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) of Hereditary Angioedema across the seven major markets?

What are the key factors driving the epidemiological trend of Hereditary Angioedema?
What will be the growth rate of Hereditary Angioedema patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed Hereditary Angioedema drugs and what are their market performance?

What are the key pipeline Hereditary Angioedema drugs and how are they expected to perform in the coming years?

How safe are the current marketed Hereditary Angioedema drugs and what are their efficacies?

How safe are the late-stage pipeline Hereditary Angioedema drugs and what are their efficacies?

What are the current treatment guidelines for Hereditary Angioedema drugs across the seven major markets?

Who are the key companies in the Hereditary Angioedema market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Hereditary Angioedema market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 HEREDITARY ANGIOEDEMA - INTRODUCTION

- 4.1 Overview
- 4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.3 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.4 Competitive Intelligence

5 HEREDITARY ANGIOEDEMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 HEREDITARY ANGIOEDEMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets

- 7.2.1 Epidemiology Scenario (2018-2023)
- 7.2.2 Epidemiology Forecast (2024-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)

8 HEREDITARY ANGIOEDEMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Hereditary Angioedema Guidelines, Management and Treatment
- 8.2 Hereditary Angioedema Treatment Algorithm

9 HEREDITARY ANGIOEDEMA - UNMET NEEDS

10 HEREDITARY ANGIOEDEMA - KEY ENDPOINTS OF TREATMENT

11 HEREDITARY ANGIOEDEMA - MARKETED PRODUCTS

- 11.1 List of Hereditary Angioedema Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name - Company Name
 - 11.1.1.1 Drug Overview

- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 HEREDITARY ANGIOEDEMA - PIPELINE DRUGS

12.1 List of Hereditary Angioedema Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Drug Name - Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. HEREDITARY ANGIOEDEMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14 HEREDITARY ANGIOEDEMA - MARKET SCENARIO

- 14.1 Market Scenario - Key Insights
- 14.2 Market Scenario - Top 7 Markets
 - 14.2.1 Hereditary Angioedema - Market Size
 - 14.2.1.1 Market Size (2018-2023)
 - 14.2.1.2 Market Forecast (2024-2034)
 - 14.2.2 Hereditary Angioedema - Market Size by Therapies
 - 14.2.2.1 Market Size by Therapies (2018-2023)
 - 14.2.2.2 Market Forecast by Therapies (2024-2034)
- 14.3 Market Scenario - United States
 - 14.3.1 Hereditary Angioedema - Market Size
 - 14.3.1.1 Market Size (2018-2023)
 - 14.3.1.2 Market Forecast (2024-2034)
 - 14.3.2 Hereditary Angioedema - Market Size by Therapies
 - 14.3.2.1 Market Size by Therapies (2018-2023)
 - 14.3.2.2 Market Forecast by Therapies (2024-2034)
 - 14.3.3 Hereditary Angioedema - Access and Reimbursement Overview
- 14.4 Market Scenario - Germany

- 14.4.1 Hereditary Angioedema - Market Size
 - 14.4.1.1 Market Size (2018-2023)
 - 14.4.1.2 Market Forecast (2024-2034)
- 14.4.2 Hereditary Angioedema - Market Size by Therapies
 - 14.4.2.1 Market Size by Therapies (2018-2023)
 - 14.4.2.2 Market Forecast by Therapies (2024-2034)
- 14.4.3 Hereditary Angioedema - Access and Reimbursement Overview
- 14.5 Market Scenario - France
 - 14.5.1 Hereditary Angioedema - Market Size
 - 14.5.1.1 Market Size (2018-2023)
 - 14.5.1.2 Market Forecast (2024-2034)
 - 14.5.2 Hereditary Angioedema - Market Size by Therapies
 - 14.5.2.1 Market Size by Therapies (2018-2023)
 - 14.5.2.2 Market Forecast by Therapies (2024-2034)
 - 14.5.3 Hereditary Angioedema - Access and Reimbursement Overview
- 14.6 Market Scenario - United Kingdom
 - 14.6.1 Hereditary Angioedema - Market Size
 - 14.6.1.1 Market Size (2018-2023)
 - 14.6.1.2 Market Forecast (2024-2034)
 - 14.6.2 Hereditary Angioedema - Market Size by Therapies
 - 14.6.2.1 Market Size by Therapies (2018-2023)
 - 14.6.2.2 Market Forecast by Therapies (2024-2034)
 - 14.6.3 Hereditary Angioedema - Access and Reimbursement Overview
- 14.7 Market Scenario - Italy
 - 14.7.1 Hereditary Angioedema - Market Size
 - 14.7.1.1 Market Size (2018-2023)
 - 14.7.1.2 Market Forecast (2024-2034)
 - 14.7.2 Hereditary Angioedema - Market Size by Therapies
 - 14.7.2.1 Market Size by Therapies (2018-2023)
 - 14.7.2.2 Market Forecast by Therapies (2024-2034)
 - 14.7.3 Hereditary Angioedema - Access and Reimbursement Overview
- 14.8 Market Scenario - Spain
 - 14.8.1 Hereditary Angioedema - Market Size
 - 14.8.1.1 Market Size (2018-2023)
 - 14.8.1.2 Market Forecast (2024-2034)
 - 14.8.2 Hereditary Angioedema - Market Size by Therapies
 - 14.8.2.1 Market Size by Therapies (2018-2023)
 - 14.8.2.2 Market Forecast by Therapies (2024-2034)
 - 14.8.3 Hereditary Angioedema - Access and Reimbursement Overview

14.9 Market Scenario - Japan

14.9.1 Hereditary Angioedema - Market Size

14.9.1.1 Market Size (2018-2023)

14.9.1.2 Market Forecast (2024-2034)

14.9.2 Hereditary Angioedema - Market Size by Therapies

14.9.2.1 Market Size by Therapies (2018-2023)

14.9.2.2 Market Forecast by Therapies (2024-2034)

14.9.3 Hereditary Angioedema - Access and Reimbursement Overview

15 HEREDITARY ANGIOEDEMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

16 HEREDITARY ANGIOEDEMA MARKET - SWOT ANALYSIS

16.1 Strengths

16.2 Weaknesses

16.3 Opportunities

16.4 Threats

17 APPENDIX

I would like to order

Product name: Hereditary Angioedema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/HD5E4276B1A0EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HD5E4276B1A0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

